Thursday, December 02, 2021 10:06 AM

Related Stories

New CASARIA Award Focuses on Colorectal and Prostate Cancer Research

MONTREAL, Dec. 2 /CNW/ - The Canadian Radiation Oncology Foundation and sanofi-aventis are pleased to announce the recipients of the first Canadian Radiation Oncology Foundation/sanofi-aventis Research Innovation Award (CASARIA).   This award promotes innovative Canadian research into new anticancer medicines and targeted radiation therapy by making $140,000 in grants available for research focusing on colorectal or prostate cancer.

"We are very proud to support the CASARIA award and the innovative research that it promotes in the areas of colorectal and prostate cancer," said Hugh O'Neill, President and CEO of sanofi-aventis. "At sanofi-aventis we are dedicated to making a difference in the lives of cancer patients and their families and it is this type of research that will help us to continue to make this commitment for years to come."

Thirty research proposals focusing on colorectal or prostate cancer were received from applicants and were reviewed to ensure they met the eligibility criteria. In the end, seven research proposals were recommended for funding on the basis of scientific merit, feasibility and relevance to Canadian radiation oncology.

"We look forward to witnessing the considerable long-term benefits to patients with colorectal and prostate cancers that this type of research grant will afford," said Ida Ackerman, President of the Canadian Radiation Oncology Foundation.  "Our foundation is proud of the creation of the CASARIA award and is delighted with the opportunity to partner with sanofi-aventis in this important endeavor."

An estimated 24,600 men will be diagnosed with prostate cancer this year, which is the most common cancer among Canadian men (excluding non-melanoma skin cancer).1 Overall, colorectal cancer is the second leading cause of cancer death in Canada.  This year, an estimated 22,500 Canadians will be diagnosed with colorectal cancer and 9,100 will die from it.2

The 2010 CASARIA award recipients are:

Dr. Alexander Louie
London Regional Cancer Centre
London, Ontario

Subject of research: Construction and validation of patient specific RTOG genitourinary and gastrointestinal CT atlases for radiotherapy treatment planning

Dr. Michael McKenzie
Dr. Caroline Chung
BC Cancer Agency
Vancouver, British Columbia

Subject of research: Imaging Tumour Hypoxia: Feasibility of EF5-PET in Prostate Cancer

Dr. Mira Keyes
BC Cancer Agency
Vancouver, British Columbia

Subject of research: Identification of DNA variants, Gene Expressions Associated, and DNA Aneuploidy with poor outcomes after Prostate Brachytherapy

Dr. Rebecca Wong
Princess Margaret Hospital
Toronto, Ontario

Subject of research: A Phase I/II study of high dose rate brachytherapy for the palliation of rectal cancer

Dr. Ronny Leone Rotondo
Jewish Hospital, McGill
Montréal, Québec

Subject of research: Phase II study evaluating the prognostic significance of intra-treatment prostate specific-antigen changes and the level of circulating tumor cells in prostate cancer patients undergoing salvage radiotherapy for post-prostatectomy biochemical failure

Tim Craig, PhD
Princess Margaret Hospital
Toronto, Ontario

Subject of research: Post-Operative Adaptive Radiation Therapy for Localized Prostate Cancer

Dr. Wilson Roa
Cross Cancer Institute
Edmonton, Alberta

Subject of research: Translational Application of Nanoparticale Radiosensitizer

About The Canadian Radiation Oncology Foundation (CROF)
The Canadian Radiation Oncology Foundation is a not-for-profit charitable organization, working with the public and the oncology community through a broad educational program to enhance public awareness of the crucial role of radiation oncology in national cancer care. Through its support for professional education and scientific research in radiation medicine, CROF aims to provide Canadians with the highest standard of radiation treatment, with the ultimate goal of reducing the burden and suffering of all Canadians diagnosed with cancer.

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.

Sanofi-aventis is represented in Canada by the pharmaceutical company sanofi-aventis Canada Inc., based in Laval, Quebec, and by the vaccines company Sanofi Pasteur Limited, based in Toronto, Ontario. Together they employ more than 2,000 people across the country. With combined R&D investments of $211.5 million in 2008, they are leaders in Canada's biopharmaceutical sector, a critical knowledge-based industry that generates jobs, business and opportunity throughout the country.

1 Canadian Cancer Society

2 Colorectal Cancer Association of Canada

Karen Nussbaum     Jennifer Ouellette
Mansfield Communications     Mansfield Communications
416-599-0024, ext. 227    416-599-0024, ext. 240

(Source: CNW )
(Source: Quotemedia)


Symbol :


Market news:

  • Heavy snow hits air travel, roads across Europe Dec 18, 2021 07:13 AM

    • LONDON - Authorities say air travel across Europe has been disrupted by heavy snow, while rail services and roads were also affected by the blast of wintry weather.
    • In Britain, London's Gatwick airport closed its runway due to snow, while British Airways suspended all flights from London's Heathrow airport.
    • In a statement, Heathrow said more snow was expected and that staff were "planning for the worst."
      • Top US officer says Iran still driving for a bomb Dec 18, 2021 06:58 AM

        • MANAMA, Bahrain - Iran is trying to build a nuclear bomb, posing a threat to its neighbors, and the United States is "very ready" to counter Iran should it make a move, the top U.S. military officer said Saturday.
        • "The United States takes very seriously our security commitments in the Gulf region," Mullen said following a meeting with Bahrain's king.
        • Bahrain, directly across the Gulf from Iran, is home to a large U.S. Navy base that would be on the front lines of any war with Iran.
          • Obama pushes for nuke treaty ratification Dec 18, 2021 06:35 AM

            • WASHINGTON - President Barack Obama is warning that failure to ratify a new arms control treaty with Russia will undercut American leadership on scores of challenges it faces worldwide.
            • Obama used his weekly radio and Internet address Saturday to plead with the Senate to approve the treaty, a dearly held foreign policy priority in the waning days of Congress' lame-duck session.
            • Obama said without action on the pact, known as New START, "we'll risk undermining American leadership not only on nuclear proliferation, but a host of other challenges around the world."
              • US lawmakers may vote on Armenian genocide measure Dec 18, 2021 06:06 AM

                • WASHINGTON - The House may vote next week on a measure that could damage U.S. relations with critical ally Turkey: a resolution declaring the World War I-era killings of Armenians a genocide.
                • House Democratic leaders had long set aside consideration of the draft resolution, and the measure was expected to expire as a new Republican-led House takes office next month.
                • House aides, speaking on condition of anonymity because they were not authorized to comment, said Friday that Democratic leaders have been discussing a possible vote with lawmakers.
                  • Senate nears repeal of military's curbs on gays Dec 18, 2021 06:06 AM

                    • WASHINGTON - Congress is close to ending the ban on gays serving openly in the military, with the Senate ready for a landmark vote that could deliver a major victory to the gay community, liberals and President Barack Obama.
                    • Senators planned a procedural vote Saturday on a bill ending the Pentagon's "don't ask, don't tell" policy as lawmakers held an unusual weekend session in their race to finish the year's legislative business.
                    • If at least 60 senators vote to advance the bill as expected, the repeal, which passed the House this week, could win final passage by late afternoon.

                      More news


    Recent Estimates

AnalystFirm NameSymbolEPS Estimate
jomariXXXXX CVG$0.31
mrbilltraderXXXXX POT$1.59
sam farahanXXXXX TECD$0.95
adfgafg ERTS$0.48